Weight-loss drugs could stop hormone replacement therapy from working and increase the associated risks, guidance has warned.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Blockbuster weight loss jabs could make contraception less effective, and prove harmful to unborn babies, according to an ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Ozempic and other GLP-1 drugs have forever altered the way people view, manage, and speak about obesity. However, it’s ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

Nearly 16 million Americans have the most deadly type of liver disease - metabolic dysfunction-associated steatohepatitis ...